We are live on ! Find out more
GRI

GRI Bio
GRI

6 hedge funds and large institutions have $64.7K invested in GRI Bio in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

339% more capital invested

Capital invested by funds: $14.7K → $64.7K (+$49.9K)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0.42% less ownership

Funds ownership: 2.37% → 1.95% (-0.42%)

14% less funds holding

Funds holding: 7 → 6 (-1)

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$65.6K
2
UBS Group
UBS Group
Switzerland
+$32.5K
3
TRCT
Tower Research Capital (TRC)
New York
+$3.57K
4
DB
Danske Bank
Denmark
+$7

Top Sellers

Rank Fund Capital Flow
1
SG
StoneX Group
New York
-$4.01K
2
Bank of America
Bank of America
North Carolina
-$5
3
BlackRock
BlackRock
New York
-$4

GRI Hedge Fund Activity: Q1 2026 in Review

6 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in GRI Bio (GRI) for Q1 2026, worth a combined $64.7K — up 339% from $14.7K a quarter earlier.

Fund positioning in GRI was balanced in Q1 2026: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $65.6K. The largest seller was StoneX Group, exiting entirely with an estimated $4.01K sold.

  • 6 institutional investors held GRI Bio (GRI) as of Q1 2026, down from 7 in Q4 2025.
  • Funds reported $64.7K of GRI Bio stock for Q1 2026, up 339% quarter-over-quarter.
  • 2 funds opened new GRI Bio positions in Q1 2026 and 2 closed out, a net change of 0 holders.
  • The largest GRI Bio buyer in Q1 2026 was Geode Capital Management, an estimated $65.6K added.
  • The largest GRI Bio seller in Q1 2026 was StoneX Group, an estimated $4.01K sold.

Based on aggregated 13F filings for Q1 2026.